Serum levels of soluble interleukin-2 receptor in renal cell carcinoma

Urology

Volumn 51, Issue 1, 1998, Pages 145-149

  Matsumoto, Takashi ^b   Furukawa, Atsuko ^b   Sumiyoshi, Yoshiteru ^b   Akiyama, Kin Y A ^b   Kanayama, Hiro Omi ^b   Kagawa, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, INTERLEUKIN-2; SURVIVAL RATE;

EID: 0031891806     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00476-7     Document Type: Article

References (21)

1. Morgan DA, Ruscetti FW, and Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007-1008, 1976.
2. Sharon M, Klausner RD, Cullen BR, Chizzonite R, and Leonard WJ: Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234: 859-863, 1986.
3. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, and Sugamura K: Cloning of the γ chain of the human IL-2 receptor. Science 257: 379-382, 1992.
4. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, and Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177, 1985.
5. Greene WC, Leonard WJ, Depper JM, Nelson DL, and Waldmann TA: The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med 105: 560-572, 1986.
6. Honda M, Yamamoto N, Nagao S, and Tokunaga T: High levels of soluble interleukin-2 receptors released from human retrovirus-infected cells. Jpn J Cancer Res 78: 889-893, 1987.
7. Setoyama Y, Imai J, Ishikawa T, Sakaida H, Takaori-Kondo A, Kawamata S, and Uchiyama T: Usefulness of the measurement of serum soluble IL-2 receptor α chain levels in clinical monitoring of non-Hodgkin lymphoma. Jpn J Clin Pathol 42: 834-842, 1994.
8. Elsässer-Beile U, Gallati H, Weber W, Wild ED, Schulte Mönting J, and von Kleist S: Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumor Biol 15: 17-24, 1994.
9. Sharma S, Saha K, Shinghal RN, and Malik GB: Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expres-sion on blood lymphocytes and lymphocytic infiltration within the tumour. Cancer Immunol Immunother 33: 198-202, 1991.
10. Wolf RE, and Brelsford WG: Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 31: 729-735, 1988.
11. Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, Matsuoka M, Hattori T, Takatsuki K, and Purtilo D: Soluble interleukin-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71: 1021-1026, 1988.
12. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, and Tura S: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 88: 770-777, 1994.
13. Lai KN, Ho S, Leung JC, and Tsao SY: Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer 67: 2180-2185, 1991.
14. Pavlidis N, Nicolaides C, Bairaktari E, Kalef-Ezra J, Athanassiadis A, Seferiadis C, and Fountzilas G: Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma. Int J Biol Markers 11: 6-11, 1996.
15. Pavlidis NA, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, and Fountzilas G: Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. Int J Biol Markers 10: 75-80, 1995.
16. Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V, and Pfreundschuh M: Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol 2 (suppl 2): 43-47, 1991.
17. Akiyama K, Tsuji M, Kurokawa Y, Yokota K, Kojima K, Naruo S, Kanayama H, and Kagawa S: The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi 88: 473-478, 1997.
18. Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, and Yanase M: Interleukin-6 in renal cell carcinoma. J Urol 148: 1778-1782, 1992.
19. Hamao T, Kanayama H, Kan M, Takigawa H, and Kagawa S: Serum levels and gene expressions of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in human renal cell carcinomas. Nippon Hinyokika Gakkai Zasshi 85: 563-570, 1994.
20. Blay JY, Negrier S, Combaret V, Attari S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J-M, Moskovtchenko J-F, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
21. Gooding R, Riches P, Dadian G, Moore J, and Gore M: Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 72: 452-455, 1995.